EGFR and lung carcinoma: Considering the fact that the EGFR-T790M mutation occurs in a large population (60–70%) of EGFR-mutated lung cancer patients who acquired resistance to first-generation EGFR-TKIs gefitinib and erlotinib10, these observations suggest that mechanisms of osimertinib resistance are much more diverse, and thus acquired osimertinib resistance may be harder to be controlled.